Search Results for "diagnosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Lumasiran: Kidney Related Outcomes
Standard response letter on lumasiran and kidney-related measures such as eGFR, kidney stone event rates, and nephrocalcinosis across clinical trials.
Standard response letter on lumasiran and kidney-related measures such as eGFR, kidney stone event rates, and nephrocalcinosis across clinical trials.
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Efficacy and Safety of Vutrisiran and Patisiran
Standard response letter on the efficacy and safety of vutrisiran and patisiran, summarizing data from the HELIOS-A study and the APOLLO study.
Standard response letter on the efficacy and safety of vutrisiran and patisiran, summarizing data from the HELIOS-A study and the APOLLO study.
Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile
Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.
Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.
Patisiran: Hospitalization and Mortality
Standard response letter on hospitalization and mortality data from patisiran clinical trials.
Standard response letter on hospitalization and mortality data from patisiran clinical trials.
Insights from the phase 3 HELIOS-A study of Vutrisiran in patients with hATTR-PN.
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
Vutrisiran: Cardiac Biomarkers in HELIOS-B
Standard response letter on exploratory cardiac biomarker analyses in HELIOS-B.
Standard response letter on exploratory cardiac biomarker analyses in HELIOS-B.
Vutrisiran: Concomitant Use with Tafamidis
Standard response letter on vutrisiran and concomitant use with tafamidis.
Standard response letter on vutrisiran and concomitant use with tafamidis.
Lumasiran: ILLUMINATE-A Study Overview
Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-A, a study evaluating the efficacy and safety of lumasiran in adults and children who are 6 years of age or older with PH1.
Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-A, a study evaluating the efficacy and safety of lumasiran in adults and children who are 6 years of age or older with PH1.
